A Critical Look at MDMA, Ketamine, and Ibogaine — and the Industry’s Greed
In the early 2000s, a promise echoed through the burgeoning psychedelic community: MDMA, the euphoria-inducing compound known colloquially as ecstasy, would revolutionize mental health treatment. Rick Doblin, founder of the Multidisciplinary Association for Psychedelic Studies (MAPS), stood at the forefront of this movement, vowing to “bring MDMA to the masses” and make psychotherapy more effective and affordable. Two decades later, as MDMA-assisted therapy inches closer to FDA approval, many early believers find themselves disillusioned, questioning whether the psychedelic renaissance has lost its way.
The Rise of MAPS and the MDMA Promise
MAPS, under Doblin’s leadership, has been instrumental in pushing MDMA-assisted therapy through clinical trials — in recent years. Their approach combines the administration of MDMA with psychotherapy sessions, aiming to treat conditions like PTSD more effectively than by alternative methods that didn’t exist in the 1990s but which are currently considered the standard of care. The initial pitch was compelling: MDMA would make rather-ineffective therapy more impactful and empathetic, reducing costs and increasing accessibility. Doblin even touted that MDMA could make therapists have more empathy, which he claimed was the real basis of MDMA’s effectiveness to whomever would listen.
However, as the years passed, the reality began to diverge from the promise. One former supporter, who claims to have manufactured MDMA illegally from 1999 to 2009, recounts their disillusionment: “When I emerged from healing myself from deep depression by 2021, in the wake of my being exiled from psychedelic culture for being busted for making MDMA for a decade — the culture around MAPS had changed.”
This individual, speaking on condition of anonymity due to their past illegal activities, describes a shift in MAPS’ focus. “With all the help money could buy, Doblin had refined his fundraising to an art over all those years,” they assert. The organization, once seen as a beacon of hope for affordable mental health treatment, now faces accusations of prioritizing fundraising and public relations over its original mission.
The Cost Paradox
Perhaps the most glaring contradiction in the MDMA therapy narrative is the issue of cost. Early advocates were led to believe MDMA-assisted therapy would be an affordable alternative to traditional, often ineffective, long-term psychotherapy as “the only” alternative as Doblin would frame it. The reality, however, paints a different picture.
Current estimates suggest that a course of MDMA-assisted therapy could cost around $5,000. For many critics, this price tag is a far cry from the accessibility once promised. “With actual costs of pennies per dose, $5000 for healing is going backwards!” our anonymous source exclaimed. This sentiment echoes throughout the psychedelic community, with many questioning how a substance so affordable — sometimes available for as little as $6/dose even in the underground market for “pure MDMA” to produce — could result in such expensive treatment.
The high cost isn’t just a matter of profit margins. It reflects the complex infrastructure required for this type of therapy, including trained therapists, controlled settings, and regulatory compliance. However, critics argue this model inherently limits access, potentially leaving behind the very populations that could benefit most from innovative mental health treatments.
Ethical Concerns and Allegations of Abuse
As MAPS grew in prominence and funding, it also became embroiled in controversy. Allegations of sexual misconduct within MDMA therapy sessions began to surface, a decade’s old pattern, raising serious ethical concerns about the vulnerability of patients in altered states of consciousness.
Our source asserts “Doblin hasn’t acknowledged the abuse, did more to cover up.” While these claims are made by a living, breathing person, they point to a broader issue within the psychedelic therapy movement: the potential for abuse in inherently vulnerable therapeutic settings.
Critics argue that MAPS’ response to these allegations has been insufficient, prioritizing the organization’s image over patient safety. “Doblin’s way was to create an enemy?! — who only called for better protocols to prevent sexual misconduct!” our source contends, suggesting that valid criticism has been met with defensiveness rather than constructive change.
The Darker Side of the Psychedelic Renaissance
As the psychedelic movement gained momentum and mainstream acceptance, a troubling trend emerged. Historically, classic psychedelics like LSD, psilocybin, and mescaline were rarely associated with direct fatalities when used in most settings. However, the landscape has shifted dramatically in recent years, driven by two main factors: the creation of novel synthetic psychedelics in academic labs and the commercialization of traditional plant medicines.
The NBOMe Tragedy
The synthesis of NBOMe compounds in academic laboratories marked a turning point in psychedelic safety. These potent substances, often sold as LSD, have been linked to numerous deaths and severe adverse reactions. Unlike traditional psychedelics, NBOMes have a much narrower safety margin, with respect to dosage, making accidental overdoses more likely and potentially fatal.
Our anonymous source reflects, “The creation of NBOMe in academic labs opened a Pandora’s box. Suddenly, we were seeing deaths directly attributable to psychedelic use, something that was almost unheard of with LSD, MDMA, and shrooms.”
Ibogaine: Powerful Medicine Meets Venture Capital
Ibogaine, a powerful psychedelic derived from the iboga plant, has long been used in traditional African spiritual practices and gained attention for its potential in treating addiction. However, its integration into Western medical paradigms, fueled by venture capital investment, has led to concerning outcomes.
“The popularization of ibogaine, now having taken multiple lives of vulnerable people, is a direct result of the VC funding boom,” our source asserts. “We’re seeing desperate individuals seeking out these treatments without fully understanding the risks.”
Indeed, several high-profile deaths associated with ibogaine treatments have raised alarm bells within the psychedelic community and beyond. These incidents often occur in unregulated or poorly regulated settings, where proper medical oversight may be lacking.
The Ketamine Conundrum
As MDMA therapy slowly navigates the regulatory landscape, ketamine clinics have proliferated across the United States. Ketamine, an anesthetic with dissociative properties, has shown promise in treating depression and other mental health conditions. However, its rapid adoption has raised concerns about safety, efficacy, and potential for abuse.
Our source, drawing on personal experience with ketamine dating back to the late 1990s, warns of its addictive potential. “Ketamine is addictive, and not enough people talking about that,” they assert. This perspective challenges the narrative often presented by ketamine clinics, which tend to downplay the risk of dependence.
The recent tragic death of actor Matthew Perry has brought these concerns into sharper focus. Perry, known for his struggles with addiction, reportedly used ketamine as part of his treatment. His death has led to indictments against medical professionals involved in his care, highlighting the potential risks of loosely regulated psychedelic therapies.
“We don’t necessarily need them to close their clinics – just stop enabling people to kill themselves with risky approaches,” our source argues, calling for stricter oversight and more honest discussions about the potential dangers of ketamine therapy.
The Case of Beond – Not Beond a Doubt
The rapid promotion of ibogaine clinics is exemplified by companies like Beond, a clinic backed by venture capital firm Focalpoint Partners. The recent Rolling Stone story highlighted the tragic loss of life that occurred while a patient sought relief from addiction at Beond’s Mexico facility. This incident underscores the potential dangers of rapidly scaling psychedelic treatments without adequate safeguards.
Our source comments, “The Beond case is a stark reminder of what can go wrong when profit motives outpace patient safety. We’re seeing vulnerable people put at risk in the name of expanding market share.”
The Commercialization of Healing
As psychedelic therapy moves from the fringes to the mainstream, concerns about commercialization and profit motives have intensified. The creation of for-profit entities like Lykos, a MAPS spin-off, has raised eyebrows within the community.
Our source views these developments with skepticism: “Rick Doblin resigning and 75% of Lykos, the MAPS spin-off that now has virtually and supposedly no control by MAPS, anymore.” This corporate restructuring, they argue, prioritizes profit over the original mission of healing and accessibility.
The choice of name for Lykos, which means “wolf” in Greek, has not gone unnoticed. “And why ‘the Wolf?’ This is one of the weirdest choices made in literally selling off the heart of what MAPS led by Doblin had claimed to be doing,” our source muses, seeing it as symbolic of a predatory turn in the industry.
A Call for a New Approach
Despite their harsh criticisms, our source hasn’t given up on the potential of psychedelic-inspired treatments. There’s something there, and many agree, but the profit potential has taken the focus off of safety — requiring education and potential risks to be communicated up-front.
This approach reflects a growing sentiment within the psychedelic community that the current medicalized, profit-driven model may not be the only — or even the best — way forward. Many are calling for a return to the grassroots, community-oriented approaches that characterized the early days of psychedelic therapy research.
In light of the troubling developments in the industry, many within the psychedelic community are calling for a reevaluation of current practices. Our source emphasizes the need for approaches that prioritize safety and ethical considerations over rapid market expansion.
“We need to step back and remember why we started this journey in the first place,” they argue. “It wasn’t about creating the next big pharmaceutical market. It was about healing and expanding consciousness in a safe, responsible manner.”
This sentiment is echoed by a growing number of researchers, practitioners, and advocates who worry the current trajectory of psychedelic therapy is veering dangerously off course. They call for:
- Stricter regulation of psychedelic clinics and treatment centers
- More comprehensive safety protocols, especially for higher-risk substances like ibogaine
- Greater transparency about the risks associated with novel psychedelics
- A return to community-based models of psychedelic use and integration
- Increased funding for independent research not tied to commercial interests
Looking to the Future
As MDMA-assisted therapy looks for the next chance for FDA approval, and the psychedelic industry continues to expand, the community finds itself at a critical juncture. The promise of revolutionary mental health treatments remains, but it’s now tempered by a sobering awareness of the risks involved.
The recent tragedies associated with even the existence of NBOMe compounds, the risks of death from ibogaine treatments, and addiction-shifting ketamine clinics serve as a stark reminder of what’s at stake. As our source puts it, “We’re not just playing with chemicals here. We’re playing with people’s lives and consciousness. We have a responsibility to get this right.”
The path forward for psychedelic therapy is far from clear. Will the industry be able to balance the drive for profitability with the imperative of patient safety? Can the original vision of accessible, transformative mental health care be realized within the current paradigm?
As these questions loom large, one thing is certain: the psychedelic community must reckon with its recent missteps and recommit to the principles of safety, ethics, and genuine healing that inspired the movement in the first place. Only then can the true potential of psychedelic therapy be realized – not as a lucrative new market, but as a profound tool for alleviating suffering and expanding human consciousness.
In the end, the true measure of success for psychedelic therapy will not be in profits generated or stocks valued, but in lives improved and suffering alleviated. It’s a standard that the current leaders of the movement would do well to remember — and one that the next generation of psychedelic researchers and practitioners must strive to honor.
Leave a Reply